J&J: positive results from phase 2/3 study

(CercleFinance.com) - Johnson & Johnson has announced positive results from the Vibrance-MG phase 2/3 study of nipocalimab in anti-AChRa positive adolescents (aged 12-17) with generalized myasthenia gravis (MGG).


Study participants treated with nipocalimab plus standard of care (SOC) achieved sustained disease control, as measured by the primary endpoint of immunoglobulin G (IgG) reduction from baseline over 24 weeks, and the secondary endpoints of improvement in MG-ADLb and QMGc scores.

These Phase 2/3 data will be the subject of an oral presentation (abstract #MG100) at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, where Johnson & Johnson will present 25 abstracts.

' 'The results show a significant reduction in IgG of around 70% in adolescents and a clinical benefit consistent with the Vivacity-MG3 study in adults,' said Jonathan Strober, M.D., Director of Clinical Services for Child Neurology and Director of the Muscular Dystrophies Clinic at UCSF Benioff Children's Hospital. '


Copyright (c) 2024 CercleFinance.com. All rights reserved.